



Express Mail No.: EV473970863US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Palese et al.	Confirmation No.:	3723
Serial No.:	10/713,732	Art Unit:	1648
Filed:	November 14, 2003	Examiner:	Mosher, Mary
For:	ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS	Attorney Docket No.:	6923-118

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

03/27/2007 TNGUYEN2 00000002 503013 10713732

01 FC:1806 Sir: 180.00 DA

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the A01-A06, B01-B04 and C01-C34 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." A copy of references B01-B04 and C01-C34 are submitted herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c)(2), Applicants estimate that a fee of \$180.00 is due in connection with the filing of this Information Disclosure Statement. The Patent Office is authorized to charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: March 23, 2007

	<u>Laura A. Coruzzi</u>	30,742
	Laura A. Coruzzi	(Reg. No.)
By:	<u>Jennifer J. Chheda</u>	46,617
	Jennifer J. Chheda	(Reg. No.)
	<b>JONES DAY</b>	
	222 East 41st Street	
	New York, New York 10017	
	(212) 326-3939	

Enclosures

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**ATTY. DOCKET NO.**

6923-118-999

**APPLICATION NO.**

10/713,732

**APPLICANT**

Palese et al.

**FILING DATE**

November 14, 2003

**ART UNIT**

1648

**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	4,567,147	1/1986	Ooi et al.	
	A02	5,766,601	6/16/98	Palese et al.	
	A03	5,882,650	3/16/99	Ennis	
	A04	6,573,079	06/03/03	Palese et al.	
	A05	6,852,522	02/08/05	Palese et al.	
	A06	2005-0054074	03/10/05	Palese et al.	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	WO 97/08292 A1	03/06/97	Univ California (Us)		
	B02	WO 99/64068 A1	12/16/99	Mt. Sinai School Medicine (US)		
	B03	WO 99/64570 A	12/16/99	Mt. Sinai School Medicine (US)		
	B04	WO 99/64571 A1	12/16/99	Mt. Sinai School Medicine (US)		

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	BRISCOE et al., 1996, Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state, EMBO J. 15:799-809	
	C02	CHANG et al., 1992, The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase, Proc. Natl. Acad. Sci USA 89:4825-4829	
	C03	CONSTANTINESCU et al., 1995, Expression and signaling specificity of the IFNAR chain of the type I interferon receptor complex, Proc. Natl. Acad. Sci. USA 92:10487-10491	
	C04	COSSINS et al., 1993, Precise Prediction of a Kk Restricted Cytotoxic T Cell Epitope in the NS1 Protein of Influenza Virus Using an NHC Allele Specific Motif, Virology, 193:289-295	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 6923-118-999	<b>APPLICATION NO.</b> 10/713,732
	<b>APPLICANT</b> Palese et al.	
	<b>FILING DATE</b> November 14, 2003	<b>ART UNIT</b> 1648

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C05	CRUSE et al, 2003, <i>Illustrated Disctionary of Immunology</i> , 2nd Edition, Cruse et al. Editors, CRC Press, pp. 367, under "Knockout Gene"	
	C06	DULBECCO et al., Editors, <i>Virology</i> , pp.77-79, 1988	
	C07	EFFERSON et al., 2006, Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. <i>J Virol.</i> 80(1):383-394	
	C08	FERKO et al., 2004, Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. <i>J Virol.</i> 78(23):13037-13045	
	C09	FENNER et al. 1974, <i>The Biology of Animal Viruses</i> 2 <sup>nd</sup> Ed. New York: Academic Press, pp 42-43	
	C10	FINN, O.L 2003, Cancer vaccines: between the idea and the reality. <i>Nature</i> 3:630-641	
	C11	GARCIA-SASTRE A. 2001, Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. <i>Virology.</i> 279(2):375-384.	
	C12	HACKETT et al., 1992, Influenza virus infection elicits class II major histocompatibility complex-restricted T cells specific for an epitope identified in the NS1 non structural protein. <i>J. of Gen. Virology</i> 73:1339-1343	
	C13	KUWANO et al., 1988, HA2 Subunit of Influenza A H1 and H2 Subtype Viruses Induces a Protective Cross Reactive Cytotoxic T Lymphocyte Response", <i>J. Immunol.</i> , 140:1264-1268	
	C14	KUWANO et al., 1990, Cross reactive protection against influenza A virus infections by an NS1-specific CTL clone, <i>Immunochemistry</i> 178:174-179	
	C15	LEWIS, 1985, Induction of anti-viral activity and specific enzymes in cell-lines derived from interferon-resistant, thymidine kinase deficient mouse L-929 cells, <i>Prog Clin Biol Res</i> 202:325-332	
	C16	LOH et al., 1994, Mutant cell lines unresponsive to alpha/beta and gamma interferon are defective in tyrosine phosphorylation of ISGF-3-alpha components, <i>Mol. Cell. Biol.</i> 14:2170-2179	
	C17	MARAMOROSH et al. 1967. <i>Methods in Virology</i> vol. 1. Ch 6. Academic Press, New York, pp 178-216	
	C18	MARCUS et al., 1994, Interferon induction: regulation by both virus and cell. <i>Hokkaido Igaku Zasshi.</i> Nov;69(6):1320-1331	
	C19	MEBATION et al. 2001, A recombinant newcastle disease virus with low-level V protein expression is immunogenic and lacks pathogenicity for chicken embryos. <i>J Virol.</i> , 5(1):420-428. .	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 6923-118-999	<b>APPLICATION NO.</b> 10/713,732
	<b>APPLICANT</b> Palese et al.	
	<b>FILING DATE</b> November 14, 2003	<b>ART UNIT</b> 1648

### NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C20	MORAHAN et al. 1970, Age-related cellular resistance of the chicken embryo to viral infections. I. Interferon and natural resistance to myxoviruses and vesicular stomatitis virus. J Infect Dis. 121(6):615-623	
	C21	MWAU et al. 2003, A review of vaccines for HIV prevention. J. Gene. Med. 5:3-10	
	C22	ORKIN et al. 1995, Report and recommendations of the panel to assess the NIH investment in research on gene therapy.	
	C23	PARK et al. 2003, Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol. 77(2):1501-1511.	
	C24	QURESHI et al., 1996, Function of Stat2 protein in transcriptional activation by alpha interferon, Mol. Cell. Biol. 16:288-293	
	C25	ROBERT-GUROFF et al. 1998, Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J. Virol. 72:10275-10280	
	C26	SHAW et al., 1982, Immunologic Studies on the Influenza A Virus Nonstructural Protein NS, J. Exp. Med., 156:243-254	
	C27	TALON et al. 2000, Influenza A and B viruses expressing altered NS1 proteins: A vaccine Approach. PNAS, 96(8):4309-4314	
	C28	VANDERMARK et al. Editors, 1986, <i>The Microbes</i> . pp 670-680	
	C29	VERMA et al., 1997, Nature, 389:239-242	
	C30	WONG et al., 1997, Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3-gamma. J.Biol. Chem. 272:28779-28785	
	C31	YANG et al., 1998, STAT3 complements defects in an interferon-resistant cell line: Evidence for an essential role for STAT3 in interferon signaling and biological activities, Proc. Natl. Acad. Sci. USA 95:5568-5572	
	C32	YANNARELL et al. 1997, Factors affecting the yield of cold-adapted influenza virus vaccine. J Virol Methods. 64(2):161-169	
	C33	YOSHIDA et al., 1981, Characterization of the RNA Associated with Influenza A Cytoplasmic Inclusions and the Interaction of NS1 Protein with RNA. Virology 110:87-97	
	C34	YOUNG et al., 1983, Efficient Expression of Influenza Virus NS1, Proc. Natl. Acad. Sci. 80:6105-6109	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	